Arthur Michael Feldman
Founder at CardioKine, Inc.
Profile
Arthur Michael Feldman is the founder of Renovacor, Inc. (founded in 2013) and CardioKine, Inc. (founded in 1998) where he holds the title of President.
Dr. Feldman is also the founder of Renovacor Holdings, Inc. Currently, Dr. Feldman is the Chairman at Sidney Kimmel Medical College.
In the past, he worked as a Director at The Johns Hopkins University and TouchStone Research, Inc. Dr. Feldman completed his undergraduate degree at Gettysburg College, his graduate degree at Louisiana State University, and his doctorate at the University of Maryland.
Arthur Michael Feldman active positions
| Companies | Position | Start |
|---|---|---|
CardioKine, Inc.
 CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Founder | 04/06/1998 |
| Sidney Kimmel Medical College | Chairman | - |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Founder | - |
Former positions of Arthur Michael Feldman
| Companies | Position | End |
|---|---|---|
TouchStone Research, Inc.
 TouchStone Research, Inc. Miscellaneous Commercial ServicesCommercial Services TouchStone Research, Inc. (formerly known as Clinical Cardiovascular Research LLC) provides contract research services to pharmaceutical and medical device companies developing cardiovascular therapies. Its services include product development consulting, clinical trial design & execution, data analysis & report writing and other services to help health care companies move their heart-helping product candidates through the development & regulatory approval process. It was founded in 1997 and is headquartered in Gaithersburg, MD | Director/Board Member | 23/10/2007 |
| RENOVACOR, INC. | Founder | - |
| The Johns Hopkins University | Director/Board Member | - |
Training of Arthur Michael Feldman
| Gettysburg College | Undergraduate Degree |
| Louisiana State University | Graduate Degree |
| University of Maryland | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
TouchStone Research, Inc.
TouchStone Research, Inc. Miscellaneous Commercial ServicesCommercial Services TouchStone Research, Inc. (formerly known as Clinical Cardiovascular Research LLC) provides contract research services to pharmaceutical and medical device companies developing cardiovascular therapies. Its services include product development consulting, clinical trial design & execution, data analysis & report writing and other services to help health care companies move their heart-helping product candidates through the development & regulatory approval process. It was founded in 1997 and is headquartered in Gaithersburg, MD | Commercial Services |
CardioKine, Inc.
CardioKine, Inc. Pharmaceuticals: MajorHealth Technology CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Health Technology |
Renovacor, Inc.
 Renovacor, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a clinical stage gene therapy company. It researches and develops AAV-based gene therapies for BAG3 gene mutation-associated diseases. Its therapeutic focus is on cardiovascular diseases. The company was founded by Arthur Michael Feldman on June 7, 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Arthur Michael Feldman
